FDA OKs Baxalta's drug for von Willebrand bleeding disorder

U.S. regulators on Tuesday approved the first genetically engineered treatment for the most common inherited bleeding disorder, von Willebrand disease. The Food and Drug Administration said that it’s approved Vonvendi, made by Baxalta Inc., for treating patients aged 18 and older.